isuzinaxib

a pan-NOX inhibitor

Also Known As:

3-phenyl-1-(pyridin-2-yl)-4-propyl-1H-5-hydroxypyrazole HCl; 3-phenyl-4-propyl-1-(2-pyridinyl)-1H-pyrazol-5-ol; 3-phenyl-4-propyl-1-(2-pyridinyl)-1H-pyrazol-5-ol hydrochloride; APX-115; APX-115 free base; EWHA-18278; EWHA-18278 free base; isuzinaxib hydrochloride

Networked: 7 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - isuzinaxib: 7
  - Pyridines: 88
    - isuzinaxib: 7

Experts

1.	Bae, Yun Soo: 5 articles (09/2019 - 03/2016)
2.	Moon, Sung Hwan: 4 articles (12/2020 - 01/2017)
3.	Lee, Soo Jin: 3 articles (12/2020 - 09/2017)
4.	Cha, Dae Ryong: 3 articles (01/2018 - 01/2017)
5.	Lee, Hwa Jeong: 2 articles (09/2019 - 03/2016)
6.	Lee, Kee-In: 2 articles (09/2019 - 03/2016)
7.	Lee, Seul Gee: 2 articles (09/2019 - 03/2016)
8.	Ha, Hunjoo: 2 articles (01/2018 - 09/2017)
9.	Kwon, Guideock: 2 articles (01/2018 - 09/2017)
10.	Lee, Jung Hwa: 2 articles (01/2018 - 09/2017)

Related Diseases

1.	Insulin Resistance 08/10/2023 - "APX-115 significantly improved insulin resistance in diabetic aging mice. " 01/01/2017 - "APX-115 significantly improved insulin resistance in diabetic mice, similar to GKT137831. "
2.	Osteoporosis 03/15/2016 - "Our results implicate Ewha-18278 as a novel therapeutic agent for the treatment of osteoporosis." 09/17/2019 - "In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. "
3.	Fibrosis (Cirrhosis) 01/01/2018 - "APX-115 treatment showed an improvement in kidney function and tubular and podocyte -injury, as well as attenuation of inflammation, fibrosis, and oxidative stress as much as losartan, a comparative drug and mainstay treatment in DKD. " 09/26/2017 - "APX-115 effectively prevented kidney injury such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, and inflammation as well as oxidative stress in diabetic mice, similar to losartan. " 08/10/2023 - "Although APX-115 did not significantly decrease albuminuria, APX-115 markedly improved mesangial expansion, macrophage infiltration, and expression of fibrosis molecules such as transforming growth factor beta 1 and plasminogen activator inhibitor 1. Interestingly, the expression of all Nox isoforms including Nox1, Nox2, and Nox4 was significantly increased in diabetic aging kidneys, and APX-115 treatment decreased Nox1, Nox2, and Nox4 protein expression in the kidney. "
4.	Diabetic Nephropathies (Diabetic Nephropathy) 09/26/2017 - "Our data suggest that APX-115, a pan-Nox inhibitor, may become a novel therapeutic agent against diabetic kidney disease by maintaining peroxisomal and mitochondrial fitness." 01/01/2017 - "Therefore, we investigated the effect of a novel pan-NOX-inhibitor, APX-115, on diabetic nephropathy in type 2 diabetic mice. " 01/01/2017 - "Our findings suggest that APX-115 may be as effective or may provide better protection than the dual Nox1/Nox4 inhibitor, and pan-Nox inhibition with APX-115 might be a promising therapy for diabetic nephropathy." 12/01/2020 - "APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice."
5.	Albuminuria 09/26/2017 - "APX-115 effectively prevented kidney injury such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, and inflammation as well as oxidative stress in diabetic mice, similar to losartan. " 08/10/2023 - "Although APX-115 did not significantly decrease albuminuria, APX-115 markedly improved mesangial expansion, macrophage infiltration, and expression of fibrosis molecules such as transforming growth factor beta 1 and plasminogen activator inhibitor 1. Interestingly, the expression of all Nox isoforms including Nox1, Nox2, and Nox4 was significantly increased in diabetic aging kidneys, and APX-115 treatment decreased Nox1, Nox2, and Nox4 protein expression in the kidney. "

Related Drugs and Biologics

1.	Protein Isoforms (Isoforms)
2.	Plasminogen Activator Inhibitor 1
3.	Transforming Growth Factor beta (TGF-beta)
4.	NADPH Oxidase 4
5.	setanaxib
6.	Losartan (Cozaar)
7.	TNF Receptor-Associated Factor 6 (TRAF6)
8.	NADPH Oxidases (NAD(P)H oxidase)
9.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics